Literature DB >> 7790673

The likelihood of recurrence in bipolar affective disorder: the importance of episode recency.

W Coryell1, J Endicott, J D Maser, T Mueller, P Lavori, M Keller.   

Abstract

These analyses used a high-intensity follow-up of of patients with bipolar affective disorder to describe the immediate and long-term risks for recurrence and the importance of sustained recovery to those risks. At the baseline evaluation, all patients were in episodes of Research Diagnostic Criteria major depressive disorder, mania or schizoaffective disorder (excluding the mainly schizophrenic subtype); those who were depressed at intake had a history of mania or schizoaffective mania. Raters re-evaluated these patients at 6-month intervals for 5 years and annually for the remainder of a 10-year follow-up. The following report describes relapse risks for the 186 patients observed to recover from their index episodes. Survival analyses quantified the likelihood of relapse over time, beginning after symptom-free periods of 4 months and 1, 2 and 3 years. Further survival analyses used treatment status as a censoring variable to estimate the eventual likelihood of recurrence among those who reported sustained compliance with lithium prophylaxis; the prophylaxis group remained under observation until they relapsed, were lost to follow-up or ceased taking lithium. Progressively longer symptom-free periods were clearly associated with lower relapse risks over the subsequent 4 years. Thereafter, however, this effect dissipitated. 7 years after recovery, the cumulative likelihood of recurrence was four in five for all bipolar patients and two in three for those whose index episode had been followed by at least 3 years without symptoms. Even with sustained lithium prophylaxis, the likelihood of at least one recurrence exceeded 70% within 5 years of recovery.(ABSTRACT TRUNCATED AT 250 WORDS)

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7790673     DOI: 10.1016/0165-0327(94)00091-m

Source DB:  PubMed          Journal:  J Affect Disord        ISSN: 0165-0327            Impact factor:   4.839


  7 in total

1.  Predictive factors for time to remission and recurrence in patients treated for acute mania: health outcomes of manic episodes (HOME) study.

Authors:  Kaan Kora; Mete Saylan; Cengiz Akkaya; Nesrin Karamustafalioglu; Nesrin Tomruk; Aziz Yasan; Timucin Oral
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2008

2.  Efficacy and feasibility of deep brain stimulation for patients with depression: A protocol for systematic review and meta-analysis.

Authors:  Hongli Zhang; Na Wang; Liping Yu; Min Zhao
Journal:  Medicine (Baltimore)       Date:  2021-05-21       Impact factor: 1.817

3.  Influence of postpartum onset on the course of mood disorders.

Authors:  Alessandro Serretti; Paolo Olgiati; Cristina Colombo
Journal:  BMC Psychiatry       Date:  2006-01-26       Impact factor: 3.630

4.  American tertiary clinic-referred bipolar II disorder versus bipolar I disorder associated with hastened depressive recurrence.

Authors:  Bernardo Dell'Osso; Saloni Shah; Dennis Do; Laura D Yuen; Farnaz Hooshmand; Po W Wang; Shefali Miller; Terence A Ketter
Journal:  Int J Bipolar Disord       Date:  2017-01-25

5.  Randomised controlled trial of Interpersonal and Social Rhythm Therapy and group-based Cognitive Remediation versus Interpersonal and Social Rhythm Therapy alone for mood disorders: study protocol.

Authors:  Katie M Douglas; Maree L Inder; Marie T Crowe; Jennifer Jordan; Dave Carlye; Cameron Lacey; Ben Beaglehole; Roger Mulder; Kate Eggleston; Katherine A Donovan; Christopher M A Frampton; Christopher R Bowie; Richard J Porter
Journal:  BMC Psychiatry       Date:  2022-02-14       Impact factor: 3.630

Review 6.  Social and environmental variables as predictors of mania: a review of longitudinal research findings.

Authors:  Sheri L Johnson; Benjamin Z S Weinberg
Journal:  Discov Ment Health       Date:  2022-03-14

7.  New approaches for the management of bipolar disorder: role of sublingual asenapine in the treatment of mania.

Authors:  Calvert G Warren; Steven L Dubovsky
Journal:  Neuropsychiatr Dis Treat       Date:  2013-05-24       Impact factor: 2.570

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.